-
Je něco špatně v tomto záznamu ?
Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum†
A. Diukendjieva, MM. Zaharieva, M. Mori, P. Alov, I. Tsakovska, T. Pencheva, H. Najdenski, V. Křen, C. Felici, F. Bufalieri, L. Di Marcotullio, B. Botta, M. Botta, I. Pajeva,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
DCM#577/17.08.2018
Bulgarian Ministry of Education and Science, National Research Program "Healthy Foods for a Strong Bio-Economy and Quality of Life"
STSM grant to Antonia Diukendjieva
COST Action CM 1407 "Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery"
#IG20801 to Lucia Di Marcotullio
Associazione Italiana Ricerca Cancro (AIRC)
18-00150S to Vladimir Kren
Czech Science Foundation
NLK
Directory of Open Access Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2012-03-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
PubMed
32380762
DOI
10.3390/antiox9050384
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Silymarin is the standardized extract from the fruits of Silybum marianum (L.) Gaertn., a well-known hepatoprotectant and antioxidant. Recently, bioactive compounds of silymarin, i.e., silybins and their 2,3-dehydro derivatives, have been shown to exert anticancer activities, yet with unclear mechanisms. This study combines in silico and in vitro methods to reveal the potential interactions of optically pure silybins and dehydrosilybins with novel protein targets. The shape and chemical similarity with approved drugs were evaluated in silico, and the potential for interaction with the Hedgehog pathway receptor Smoothened (SMO) and BRAF kinase was confirmed by molecular docking. In vitro studies on SMO and BRAF V600E kinase activity and in BRAF V600E A-375 human melanoma cell lines were further performed to examine their effects on these proteins and cancer cell lines and to corroborate computational predictions. Our in silico results direct to new potential targets of silymarin constituents as dual inhibitors of BRAF and SMO, two major targets in anticancer therapy. The experimental studies confirm that BRAF kinase and SMO may be involved in mechanisms of anticancer activities, demonstrating dose-dependent profiles, with dehydrosilybins showing stronger effects than silybins. The results of this work outline the dual SMO/BRAF effect of flavonolignans from Silybum marianum with potential clinical significance. Our approach can be applied to other natural products to reveal their potential targets and mechanism of action.
Department of Chemistry and Technology of Drugs Sapienza University of Rome 00185 Rome Italy
Department of Molecular Medicine Sapienza University of Rome 00161 Rome Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20019230
- 003
- CZ-PrNML
- 005
- 20201123123830.0
- 007
- ta
- 008
- 201103s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/antiox9050384 $2 doi
- 035 __
- $a (PubMed)32380762
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Diukendjieva, Antonia $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 245 10
- $a Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum† / $c A. Diukendjieva, MM. Zaharieva, M. Mori, P. Alov, I. Tsakovska, T. Pencheva, H. Najdenski, V. Křen, C. Felici, F. Bufalieri, L. Di Marcotullio, B. Botta, M. Botta, I. Pajeva,
- 520 9_
- $a Silymarin is the standardized extract from the fruits of Silybum marianum (L.) Gaertn., a well-known hepatoprotectant and antioxidant. Recently, bioactive compounds of silymarin, i.e., silybins and their 2,3-dehydro derivatives, have been shown to exert anticancer activities, yet with unclear mechanisms. This study combines in silico and in vitro methods to reveal the potential interactions of optically pure silybins and dehydrosilybins with novel protein targets. The shape and chemical similarity with approved drugs were evaluated in silico, and the potential for interaction with the Hedgehog pathway receptor Smoothened (SMO) and BRAF kinase was confirmed by molecular docking. In vitro studies on SMO and BRAF V600E kinase activity and in BRAF V600E A-375 human melanoma cell lines were further performed to examine their effects on these proteins and cancer cell lines and to corroborate computational predictions. Our in silico results direct to new potential targets of silymarin constituents as dual inhibitors of BRAF and SMO, two major targets in anticancer therapy. The experimental studies confirm that BRAF kinase and SMO may be involved in mechanisms of anticancer activities, demonstrating dose-dependent profiles, with dehydrosilybins showing stronger effects than silybins. The results of this work outline the dual SMO/BRAF effect of flavonolignans from Silybum marianum with potential clinical significance. Our approach can be applied to other natural products to reveal their potential targets and mechanism of action.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zaharieva, Maya M $u Department of Infectious Microbiology, Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 700 1_
- $a Mori, Mattia $u Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, 53100 Siena, Italy.
- 700 1_
- $a Alov, Petko $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 700 1_
- $a Tsakovska, Ivanka $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 700 1_
- $a Pencheva, Tania $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 700 1_
- $a Najdenski, Hristo $u Department of Infectious Microbiology, Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 700 1_
- $a Křen, Vladimír $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, 14220 Prague, Czech Republic.
- 700 1_
- $a Felici, Chiara $u Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
- 700 1_
- $a Bufalieri, Francesca $u Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
- 700 1_
- $a Di Marcotullio, Lucia $u Department of Molecular Medicine, Laboratory Affiliated to Istituto Pasteur Italia Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy.
- 700 1_
- $a Botta, Bruno $u Department of Chemistry and Technology of Drugs, Sapienza University of Rome, 00185 Rome, Italy.
- 700 1_
- $a Botta, Maurizio $u Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, 53100 Siena, Italy.
- 700 1_
- $a Pajeva, Ilza $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- 773 0_
- $w MED00200130 $t Antioxidants (Basel, Switzerland) $x 2076-3921 $g Roč. 9, č. 5 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32380762 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201103 $b ABA008
- 991 __
- $a 20201123123829 $b ABA008
- 999 __
- $a ind $b bmc $g 1586010 $s 1109428
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 9 $c 5 $e 20200505 $i 2076-3921 $m Antioxidants $n Antioxidants $x MED00200130
- GRA __
- $a DCM#577/17.08.2018 $p Bulgarian Ministry of Education and Science, National Research Program "Healthy Foods for a Strong Bio-Economy and Quality of Life"
- GRA __
- $a STSM grant to Antonia Diukendjieva $p COST Action CM 1407 "Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery"
- GRA __
- $a #IG20801 to Lucia Di Marcotullio $p Associazione Italiana Ricerca Cancro (AIRC)
- GRA __
- $a 18-00150S to Vladimir Kren $p Czech Science Foundation
- LZP __
- $a Pubmed-20201103